Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Abstract Introduction Lebrikizumab and dupilumab are monoclonal antibodies approved for treating moderate-to-severe atopic dermatitis (AD). Both have demonstrated efficacy and safety over the 16-week SOLOs and ADvocate trials. However, AD is a chronic and relapsing inflammatory disease, and the long...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José-Carlos Armario-Hita
Format:	Artigo
Język:	Inglês
Wydane:	Adis, Springer Healthcare 2023-10-01
Seria:	Dermatology and Therapy
Hasła przedmiotowe:	Atopic dermatitis Dupilumab Eczema Lebrikizumab Matching-adjusted indirect comparison
Dostęp online:	https://doi.org/10.1007/s13555-023-01058-z
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!